Table 3 from INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

2026 Open access

Read full text
Authors: Danny Rischin, Aaron Richard Hansen, Ezra E.W. Cohen, Makoto Tahara, Kevin Joseph Harrington, Robert I. Haddad, Lisa Francesca Licitra, Hisham Mohamed Mehanna, Robert Louis Ferris, P. Koralewski, Konstantin Penkov, Michael Schenker
+12 more David Robert Spigel, Amaury Daste, Min Hee Hong, Ye Guo, Michael Jon Chisamore, Michael L. Washburn, Amy Phillips‐Jones, John Russell, Sumita Roy–Ghanta, Catherine E. Ellis, Marc S. Ballas, Christophe Le Tourneau
DOI: 10.1158/1078-0432.31744685
Cited by: 0

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Head and Neck Cancer Studies Nonmelanoma Skin Cancer Studies

Publication details

Publication date
16 March 2026
Language
EN